1027168-88-2

Basic information

• Product Name: (S)-2-((S)-1-Benzyloxycarbonylmethyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylamino)-6-[2-(tert-butoxycarbonyl-methyl-amino)-ethylamino]-hexanoic acid benzyl ester
• CAS NO: 1027168-88-2
• Molecular Weight: 700.875
• Mol File: 1027168-88-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-2-((S)-1-Benzyloxycarbonylmethyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylamino)-6-[2-(tert-butoxycarbonyl-methyl-amino)-ethylamino]-hexanoic acid benzyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-((S)-1-Benzyloxycarbonylmethyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylamino)-6-[2-(tert-butoxycarbonyl-methyl-amino)-ethylamino]-hexanoic acid benzyl ester(1027168-88-2)
• EPA Substance Registry System: (S)-2-((S)-1-Benzyloxycarbonylmethyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylamino)-6-[2-(tert-butoxycarbonyl-methyl-amino)-ethylamino]-hexanoic acid benzyl ester(1027168-88-2)

Safety Data

• Hazardous Substances Data: 1027168-88-2(Hazardous Substances Data)

Upstream product

• 123387-72-4 O-tert-butyl N-methyl-N-(2-oxoethyl)carbamate 
• 158387-21-4 6-<<(1,1-dimethylethoxy)carbonyl>amino>-2-<1-<<(benzyloxy)carbonyl>methyl>-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl>hexanoic acid benzyl ester 
• 97878-50-7 (S)-6-tert-Butoxycarbonylamino-2-((S)-1-carboxymethyl-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-ylamino)-hexanoic acid 
• 100-39-0 benzyl bromide 

Relevant articles and documents

Dual Angiotensin Converting Enzyme/Thromboxane Synthase Inhibitors

A variety of compounds were prepared to determine whether dual angiotensin converting enzyme (ACE)/thromboxane synthase (TxS) inhibition could be obtained in the same molecule.These compounds would be used to explore the concept that a dual inhibitor would have superior antihypertensive activity in the spontaneous hypertensive rat compared to an ACE inhibitor.Potent in vitro dual ACE and TxS inhibition was obtained in the same molecule with five series of compounds.Potent blood pressure lowering in the SHR was observed after oral administration of 8b and 11.However, a corre lation between blood pressure lowering and the A1 pressor response inhibition was not observed.The blood pressure-lowering actions of enalapril were significantly potentiated by concurrent administration of 3, a thromboxane synthase inhibitor.Analysis of the area under the curve for 24 h showed nearly a doubling of the blood pressure-lowering effect.